kdmf semaglutide registration Novo Nordisk's shows promise in Phase III CKD trial CagriSema - More Biotechnology

Immunity (2015) 42(2):32131

& Handelsman, D

doi:10.1111/j.1600-0749.1992.tb00540.x

What makes Mounjaro different from semaglutide-based products is that it activates two hormone receptors at once: the GLP-1 receptor (which Ozempic and Wegovy target) and the GIP receptor (which plays a role in how the body processes fat and regulates insulin response)

Rapid weight loss with GLP-1 use can impact skin elasticity, leading to sagging or loose skin

Therefore, the decision should be made in consultation with a healthcare provider, taking into account the patients overall health, existing conditions, and treatment goals